View Past Performanceco.don バランスシートの健全性財務の健全性 基準チェック /06co.donの健全性を判断するにはデータが不十分です主要情報n/a負債資本比率n/a負債インタレスト・カバレッジ・レシオn/a現金n/aエクイティn/a負債合計n/a総資産n/a財務の健全性に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Apr 20co.don AG to Report Q4, 2025 Results on Apr 21, 2026co.don AG announced that they will report Q4, 2025 results on Apr 21, 2026お知らせ • Apr 15co.don AG to Report Q4, 2025 Results on Apr 14, 2026co.don AG announced that they will report Q4, 2025 results on Apr 14, 2026お知らせ • Mar 10co.don AG to Report Q2, 2025 Results on Mar 10, 2026co.don AG announced that they will report Q2, 2025 results on Mar 10, 2026お知らせ • Feb 25co.don AG to Report Fiscal Year 2025 Results on Feb 24, 2026co.don AG announced that they will report fiscal year 2025 results on Feb 24, 2026New Risk • Oct 01New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended June 2022. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported June 2022 fiscal period end). Market cap is less than US$10m (€657.4k market cap, or US$695.0k).お知らせ • Jan 26ReLive Biotechnologies, Ltd. acquired all operating assets of co.don AG from co.don AG (XTRA:CNW).ReLive Biotechnologies, Ltd. acquired all operating assets of co.don AG from co.don AG (XTRA:CNW) on January 25, 2023. ReLive Biotechnologies, Ltd. completed the acquisition of all operating assets of co.don AG from co.don AG (XTRA:CNW) on January 25, 2023.Breakeven Date Change • Nov 30Forecast to breakeven in 2023The analyst covering co.don expects the company to break even for the first time. New forecast suggests the company will make a profit of €300.0k in 2023. Average annual earnings growth of 114% is required to achieve expected profit on schedule.Price Target Changed • Nov 17Price target decreased to €6.30Down from €7.60, the current price target is provided by 1 analyst. New target price is 31,088% above last closing price of €0.02. Stock is down 99% over the past year. The company is forecast to post a net loss per share of €0.20 next year compared to a net loss per share of €0.41 last year.Reported Earnings • Jul 12Full year 2021 earnings: EPS misses analyst expectationsFull year 2021 results: €0.41 loss per share (up from €0.85 loss in FY 2020). Revenue: €10.0m (up 61% from FY 2020). Net loss: €9.32m (loss narrowed 33% from FY 2020). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 5.1%. Over the next year, revenue is forecast to grow 66%, compared to a 28% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 54% per year, which means it is significantly lagging earnings.Price Target Changed • Apr 27Price target decreased to €5.85Down from €7.60, the current price target is an average from 2 analysts. New target price is 335% above last closing price of €1.35. Stock is down 23% over the past year. The company is forecast to post a net loss per share of €0.37 next year compared to a net loss per share of €0.85 last year.Price Target Changed • Feb 01Price target decreased to €5.85Down from €7.60, the current price target is an average from 2 analysts. New target price is 252% above last closing price of €1.66. Stock is down 34% over the past year. The company is forecast to post a net loss per share of €0.37 next year compared to a net loss per share of €0.85 last year.Price Target Changed • Jun 22Price target increased to €4.20Up from €3.80, the current price target is an average from 2 analysts. New target price is 200% above last closing price of €1.40. Stock is up 13% over the past year.Reported Earnings • May 06Full year 2020 earnings released: €0.43 loss per share (vs €0.59 loss in FY 2019)The company reported a soft full year result with increased losses and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: €7.10m (up 2.8% from FY 2019). Net loss: €13.9m (loss widened 9.8% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has fallen by 49% per year, which means it is performing significantly worse than earnings.Is New 90 Day High Low • Nov 20New 90-day high: €1.56The company is up 30% from its price of €1.20 on 21 August 2020. The German market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €3.41 per share.Is New 90 Day High Low • Oct 13New 90-day low: €0.93The company is down 28% from its price of €1.30 on 15 July 2020. The German market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is flat over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €2.53 per share.Is New 90 Day High Low • Sep 25New 90-day low: €0.99The company is down 36% from its price of €1.54 on 26 June 2020. The German market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €2.52 per share.財務状況分析短期負債: CNWの 短期資産 が 短期負債 をカバーしているかどうかを判断するにはデータが不十分です。長期負債: CNWの短期資産が 長期負債 をカバーしているかどうかを判断するにはデータが不十分です。デット・ツー・エクイティの歴史と分析負債レベル: CNWの 純負債対資本比率 を計算して 満足できる ものであるかどうかを判断するにはデータが不十分です。負債の削減: CNWの負債対資本比率が過去 5 年間で減少したかどうかを判断するにはデータが不十分です。債務返済能力: CNWの負債が 営業キャッシュフロー によって 十分にカバーされている かどうかを判断するにはデータが不十分です。インタレストカバレッジ: CNWの負債に対する 利息支払い が EBIT によって 十分にカバーされている かどうかを判断するにはデータが不十分です。貸借対照表健全な企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の健全な企業。View Dividend企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/26 08:13終値2026/05/22 00:00収益2024/09/30年間収益2024/09/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋co.don AG 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3 アナリスト機関Peter-Thilo HaslerSphene Capital GmbHUlrich HuwaldWarburg Research GmbHHarald HofWarburg Research GmbH
お知らせ • Apr 20co.don AG to Report Q4, 2025 Results on Apr 21, 2026co.don AG announced that they will report Q4, 2025 results on Apr 21, 2026
お知らせ • Apr 15co.don AG to Report Q4, 2025 Results on Apr 14, 2026co.don AG announced that they will report Q4, 2025 results on Apr 14, 2026
お知らせ • Mar 10co.don AG to Report Q2, 2025 Results on Mar 10, 2026co.don AG announced that they will report Q2, 2025 results on Mar 10, 2026
お知らせ • Feb 25co.don AG to Report Fiscal Year 2025 Results on Feb 24, 2026co.don AG announced that they will report fiscal year 2025 results on Feb 24, 2026
New Risk • Oct 01New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended June 2022. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported June 2022 fiscal period end). Market cap is less than US$10m (€657.4k market cap, or US$695.0k).
お知らせ • Jan 26ReLive Biotechnologies, Ltd. acquired all operating assets of co.don AG from co.don AG (XTRA:CNW).ReLive Biotechnologies, Ltd. acquired all operating assets of co.don AG from co.don AG (XTRA:CNW) on January 25, 2023. ReLive Biotechnologies, Ltd. completed the acquisition of all operating assets of co.don AG from co.don AG (XTRA:CNW) on January 25, 2023.
Breakeven Date Change • Nov 30Forecast to breakeven in 2023The analyst covering co.don expects the company to break even for the first time. New forecast suggests the company will make a profit of €300.0k in 2023. Average annual earnings growth of 114% is required to achieve expected profit on schedule.
Price Target Changed • Nov 17Price target decreased to €6.30Down from €7.60, the current price target is provided by 1 analyst. New target price is 31,088% above last closing price of €0.02. Stock is down 99% over the past year. The company is forecast to post a net loss per share of €0.20 next year compared to a net loss per share of €0.41 last year.
Reported Earnings • Jul 12Full year 2021 earnings: EPS misses analyst expectationsFull year 2021 results: €0.41 loss per share (up from €0.85 loss in FY 2020). Revenue: €10.0m (up 61% from FY 2020). Net loss: €9.32m (loss narrowed 33% from FY 2020). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 5.1%. Over the next year, revenue is forecast to grow 66%, compared to a 28% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 54% per year, which means it is significantly lagging earnings.
Price Target Changed • Apr 27Price target decreased to €5.85Down from €7.60, the current price target is an average from 2 analysts. New target price is 335% above last closing price of €1.35. Stock is down 23% over the past year. The company is forecast to post a net loss per share of €0.37 next year compared to a net loss per share of €0.85 last year.
Price Target Changed • Feb 01Price target decreased to €5.85Down from €7.60, the current price target is an average from 2 analysts. New target price is 252% above last closing price of €1.66. Stock is down 34% over the past year. The company is forecast to post a net loss per share of €0.37 next year compared to a net loss per share of €0.85 last year.
Price Target Changed • Jun 22Price target increased to €4.20Up from €3.80, the current price target is an average from 2 analysts. New target price is 200% above last closing price of €1.40. Stock is up 13% over the past year.
Reported Earnings • May 06Full year 2020 earnings released: €0.43 loss per share (vs €0.59 loss in FY 2019)The company reported a soft full year result with increased losses and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: €7.10m (up 2.8% from FY 2019). Net loss: €13.9m (loss widened 9.8% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has fallen by 49% per year, which means it is performing significantly worse than earnings.
Is New 90 Day High Low • Nov 20New 90-day high: €1.56The company is up 30% from its price of €1.20 on 21 August 2020. The German market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €3.41 per share.
Is New 90 Day High Low • Oct 13New 90-day low: €0.93The company is down 28% from its price of €1.30 on 15 July 2020. The German market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is flat over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €2.53 per share.
Is New 90 Day High Low • Sep 25New 90-day low: €0.99The company is down 36% from its price of €1.54 on 26 June 2020. The German market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €2.52 per share.